Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Because he’s a lawyer and the optics of that are beyond reasonable. One can talk their way out of Mikah winding down as things can change, but not a buyout like this. Not even 1% chance of this happening. If Nasrat went this route it would be an onslaught of legal pursuits against his decision making. Plus, all shareholders would have to approve. He has a real nice share, but not the majority to sway such a crappy decision.
I only object to idiotic ideas. There are plenty here. Mikah only gets part of profit split. Majority of revenue is from mfg fees, which Elite gets.
No, Nasrat is chairman. That would look like a deal significantly in his favor with the pending filings with FDA. Not a chance even if premium at today’s prices.
There’s no way Mikah can buy out Elite.
How did that work out?
Doubtful. Elite is not going to get involved in a big drawn out lawsuit if they expect to be bought out in a couple years. They want to prop up that Balance Sheet and not waste it on egregious legal fees.
Not the first time. Someone did it couple months back. I rarely look at yahoo board anymore.
Clearly a fake. Very sad.
Correct. PR was due to the materiality expected. Nasrat mentioned that in a prior call. It’s not our news to share unless we expect a big financial impact to Elite.
Why would you add it to the buyout price when the contract would end around then and has no future cash flow benefit? Doesn’t sound like Nasrat’s is expecting the agreement to be extended. If things change, only then it would make sense to be included in forward looking DCF analyses for a buyout.
That’s the total market, not our market share.
Not our product to launch. We are only a contract mfr.
And with 4/1 launch there will be some mfg fee revenue to prep for small launch quantity sent to Pyros. This means revenue associated with the launch quantities will be included in Q4 financials.
Referring to “manufactured for” vs “manufactured by”?
Not sure what you are insinuating here, but any government funding or grants would be called out in financials similar to PPA in past. Nothing new there as of yet.
Looking forward to next cc with Q4 performance and expecting a forward looking update after few months of Prasco under our belt.
Are you really worried about the direction that $35K in total shareholder value made today? Who cares.
When has Elite ever parsed out only generic market in their PRs? I don’t think Methotrexate passed the bar to file. We filed a smaller antimetabolite.
If you move back a day, you’ll hit SEC filing requirements. Fins are due by 6/30 at latest.
You mean realism? Take a look at where Adderall ER has done over several years?5%? Not even close. Why assume penetration will be closer to IR or even half of it when we can’t get there with ER?
Prasco will help move things along with ER, but this board has no sense of realism. Let’s ignore facts and simply opt for pie in the sky.
Where are we from global ambitions? Dexcel hasn’t moved going on 3 years now.
I couldn’t care less if you call me the animal of your choosing. Just so you know GOAT has a much different meaning today.
My job is to provide a balance to this board. Choose the animal of your choice.
It’s as annoying as sleuth’s running commentary of “you don’t know why you are on this board, do you?”
Be objective, be realistic. Nasrat can’t hit near term goals working with smaller drugs and the FDA and yet we believe his billion dollar market ambitions. That’s an issue. It sucks, but it’s what has actually happened. Don’t ignore what’s right under your nose.
Math is wrong from beginning. That $10 market with known drugs will shrink. Vyvanse is half of it and market will greatly shrink when generics can get API and actually start penetrating the market. The question is by how much with 10+ competitors aching to get piece of pie, 50%, 60%?
Will there be future products to grow total penetrate market beyond what we already know? Highly likely if pipeline can keep moving forward and submissions approved.
Management is protected by forward looking language. Doing what you say you intend to do, hope to do and actually doing it builds credibility. No one has a crystal ball and even regarding near term sales expectations midway through quarter have been drastically missed. I can’t tell if Nasrat is shooting from the hip in some commentary or just unrealistically optimistic, trying to prop up share price on hope, not close enough to the business or a clueless nincompoop? One thing that has been consistent is the abysmal external communication.
He also said NASDAQ many years ago. He misses self imposed timeframes and continually deflects. It’s always someone else’s fault.
They haven’t been filing them separately since SequestOx. They have been putting them in the Q’s and K’s. We may not see the CRL wording until 10K in June.
Some companies are better than others others, but it’s all Elite really has at this point, insider ownership + retail.
Retail shareholders are ignored 99% of the time.
You can find anything you want online. The sales growth will speak for itself.
It sure we’ll have any revenue from Vigabatrin. We no longer own it and are only a contract manufacturer. Time is eating away at that contract…
We did trade over 5M on 2/23/24,
8/23/23 & 8/28/23. We even hit 10M on 8/22/23. Looking forward to the daily average hitting 5M.
I don’t think original poster was saying billion shares were traded daily, but rather outstanding.
AI generated article. Dollar difference of “significant growth” in short positions is about $12K, or about 0.15% of O/S count.
You are correct. As of last 10K he listed 295M at 29.1%, which differs from recent Form 4.
Form 4’s filed today. One is amendment. Total ownership ~220M shares owned by Nasrat that have been disclosed.
Agreed we knew it was coming. I misinterpreted your comment thinking it wasn’t dilution.
Haven’t sold a single share. I haven’t day traded for while. Never did with Elite.
You do realize it was dilutive, right?
It’s payment delay, but 80M in dilutive shares to the O/S count nonetheless.
Well the 2 SEC dilutive filings from Friday might be the factor. It’s on little volume. Daily volume has been low the past few weeks now.
I didn’t say that I was, but you should have the mindset of one.
Hey noob - Because that’s the whole premise of an investor, especially activist investors that care about their investment. When something isn’t right, they aren’t lemmings, they let their voice be heard.
I don’t think either will happen. Significant amount of work to be done towards either. Perhaps later this year or early next.